Physician profile
Van D Warren
NPI 1770503849
$13,779.06
in general payments reported to CMS, 2019-2025
36 companies · $2,142 in 2025
The $2,142 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,060 · 2020: $1,923 · 2021: $2,163 · 2022: $1,278 · 2023: $1,984 · 2024: $2,229 · 2025: $2,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,124 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,124.30 |
| Education | $230.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,211.19 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,845.56 | 2019-2025 | Tavneos, Enbrel, Krystexxa |
| Pfizer INC. | $1,499.00 | 2019-2025 | |
| Ucb, INC. | $1,029.30 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $846.80 | 2019-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $804.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $754.40 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $681.60 | 2019-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $661.03 | 2019-2025 | Tremfya |
| Horizon Therapeutics Plc | $509.01 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $419.91 | 2019-2024 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $394.08 | 2019-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $391.66 | 2019-2025 | Soliris, Ultomiris, Strensiq |
| Mallinckrodt Hospital Products INC. | $350.50 | 2020-2024 | Acthar |
| Aurinia Pharma U.S., INC. | $201.79 | 2021-2024 | Lupkynis |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.36 | 2019-2025 | Cyltezo, Ofev |
| Ani Pharmaceuticals, INC. | $185.27 | 2023-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $179.28 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $135.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $75.05 | 2019 | |
| Sobi, INC | $50.79 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $50.20 | 2021 | |
| Celgene Corporation | $46.71 | 2019 | |
| Calliditas Therapeutics US INC. | $38.25 | 2025 | Tarpeyo |
| Organon LLC | $29.59 | 2025 | Hadlima, Renflexis |
| Averitas Pharma INC. | $25.10 | 2023 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $23.73 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.74 | 2025 | Opsumit |
| Otsuka America Pharmaceutical, INC. | $19.17 | 2025 | Jynarque |
| Ironwood Pharmaceuticals, INC | $18.56 | 2021 | |
| Vifor Pharma, INC. | $17.86 | 2022 | |
| Sandoz INC. | $17.53 | 2025 | Hyrimoz |
| Novo Nordisk INC | $17.30 | 2019 | |
| Alfasigma USA, INC. | $14.86 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.71 | 2019 | |
| Hikma Pharmaceuticals USA | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.